Table 2.
Primary and secondary outcomes in patients on VKAs or DOAC at COVID-19 diagnosis, before (unmatched) and after propensity score matching
| Outcomes | Initial populations | Propensity score matched populations | ||||
|---|---|---|---|---|---|---|
| COVID-19 patients on prior VKA (N = 648) |
COVID-19 patients on prior DOAC (N = 1627) |
p-value | COVID-19 patients on prior VKA (N = 635) |
COVID-19 patients on prior DOAC (N = 635) |
p-value | |
| All-cause mortality | 10 (1.54%) | 22 (1.35%) | 0.913 | 10 (1.57%) | 11 (1.73%) | 0.826 |
| ICU admission/MV necessity | 12 (1.85%) | 21 (1.29%) | 0.378 | 12 (1.89%) | 10 (1.57%) | 0.667 |
| ICH/gastrointestinal bleeding | 10 (1.54%) | 12 (0.74%) | 0.145 | 10 (1.57%) | 10 (1.57%) | 1.000 |
| Any arterial or venous thrombotic event | 91 (14.04%) | 139 (8.54%) | < 0.001 | 89 (14.02%) | 61 (9.61%) | 0.015 |
| Hospital admission | 17 (2.62%) | 42 (2.58%) | 0.891 | 17 (2.68%) | 17 (2.68%) | 1.000 |
| Myocardial infarction | 10 (1.54%) | 13 (0.80%) | 0.190 | 10 (1.57%) | 10 (1.57%) | 1.000 |
| Venous thromboembolism | 64 (9.88%) | 111 (6.82%) | 0.007 | 62 (9.76%) | 50 (7.87%) | 0.235 |
| All bleeding events | 16 (2.45%) | 18 (1.11%) | 0.084 | 16 (2.52%) | 10 (1.57%) | 0.235 |
| Ischemic stroke/TIA/SE | 27 (4.17%) | 28 (1.72%) | < 0.001 | 27 (4.25%) | 11 (1.73%) | 0.008 |
DOAC: direct-acting oral anticoagulant; ICH: intracranial haemorrhage; ICU: intensive care unit; MV: mechanical ventilation; SE: systemic embolism; TIA: transient ischemic attack; VKA: vitamin K antagonist